Clinical Trial Update: Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of selumetinib in Neurofibromatosis type II–related tumors was terminated, with results posted in 2025; the study included vestibular schwannoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Glioma
• Meningioma
• Neurofibromatosis Type Ii
• Vestibular Schwannoma

Drugs mentioned

• Selumetinib (Koselugo) (selumetinib)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Neurofibromatosis 2, Vestibular Schwannoma | Phase 2 | Status: TERMINATED | Results posted: 2025-04-22